Replies to post #549367 on NorthWest Biotherapeutics Inc (NWBO)

[CaptainObvious]

The 30th may be the last opportunity to go to a NWBO ASM

[Jackxkr]

Thst is odd.

[Goats'nCrows]

It's almost like someone else is going to go ham with it...

[meirluc]

Yes hyperopia, it would be odd for Northwest Bio not to be represented at the Glioblastoma Development Summit. Do you have a possible explanation for this?

Is it possible that by March 2023 Northwest has been swallowed up by a Leviathan and unlike Jonah, not released as a live and independent entity to the shore three days later?

But maybe that is just my wishful thinking and there are much better explanations for NWBO's absence at that summit.

[CherryTree1]

IMHO Everything relative to NWBO has been odd for the past 7 years. Can these market makers, hedge funds and big pharma thugs really be so greedy that they would do everything possible to derail what appears to be an extremely effective treatment for GBM and most other solid tumor cancers???
yes odd and
different
unusual
atypical
avant-garde
bizarre
crazy
deviant
eccentric
erratic
flaky
fluky
fragmentary
freakish
freaky
irregular
kooky
off-the-wall
out of the ordinary
outlandish
peculiar
queer
strange
uncanny
weird

[branster]

hyperopia, I see good ole Novocure is a 2023 Partner, they got to keep playing the part...

[biosectinvestor]

Very interesting H.

This is organized by a UK company that as a business organizes conferences like this, and honestly, looks more like someone trying to create a business in this “niche”, as they call their conference products. They invited large pharma and companies that would be the best sources of income first. It’s not till March and if it were an important or useful event, depending on whether NWBO is still fully independent, they could probably attend if they wanted to do so.

I vaguely think that Dr. Liau or others were maybe scheduled to attend last year but then didn’t or attended but we got no news. I vaguely remember it, but at this stage you never know what the plan is likely to be.

The reality is it also looks, generally to me, like often these sorts of events start on the East Coast and then they remember we have a West Coast, in terms of people like Dr. Liau. Who if they really wanted a top person would seek her early, but she’s actually very busy. Maybe some of these attendees that sign up first are not so busy. Or are more executives at big pharma. Some people just attend a lot of conferences looking for other companies to network with, etc., and some of those people are great talkers and have big titles and potentially access to research monies, so they are an attractor for others to register.

There could be many reasons why they are focused in certain ways. Or why a small co at this stage in its existence might not be spending a lot planning to be at conferences right now.

I do not think it is odd. I would rather with their limited means right now, that the company remain focused. Dr. Liau would be the appropriate invitee and also, since it is organized by a UK company, Dr. Ashkan.

There could be many drivers for NWBO and the various doctors to be focused elsewhere at the moment and not be planning to go to every conference from the get go. But the also could yet decide to attend or even maybe present or be a guest. I would bet a conference like this would want them more than they might want to take the time away from their schedules to attend right now.

[Tedbrogan5]

There are a couple reasons why NWBO may not be publicly reported as exhibitors (yet).
- It may just not be the caliber of conference that is worth the time, effort, $$$ and PR potential. Plausible, I guess? May want to save it all for more prominent conferences... Still, you'd hope they'd at least attend.
- They are still looking at what, if anything, they'd want to exhibit in terms of new data / studies. Plausible I guess? It would be cutting it kind of close to still be pulling something together...
- There is a buy out in the works and they don't expect to exist in March. Unlikely, but one can dream.
- They are packing it in. Unlikely.

[flipper44]

Too far to go from Bethesda to Boston.

[CrashOverride]

Why present if those who will be prescribing and selling DCVax already know it's spectacular?

[CassieW]

I used to get excited over NWBIO attending conferences- now I’m excited over them NOT attending! Let’s GO!

[HappyLibrarian]

NWBO is inconsistent about getting their name out there and is often last-minute or even late with things so the most logical explanation is that NWBO is being NWBO.

Naturally there are those who will suspect that NWBO will somehow not be around to present there in March (probably for a positive reason) but this is less likely by far.

[dmb2]

hyperopia, good find, there is obviously a change in the company coming near term. If not, shareholders may have a problem. It is obviously true that if there is an expectation of approval to market coming in 2023 this conference would normally be a major event in the pre-approval marketing plan. We all know this is the expectation for 2023, so, how will DCVax be represented at this conference? It will be represented. I fully expect to know the answers by 12/31, and am assuming this news and more is backlogged behind mfg licensing at Sawston.

I think since Covid consumed all RA's that they have been challenged to keep up with their time commitments. There is reason NWBO expected Sawston licensing by EOY and I don't think there is a major issue after receiving authorization for clinical product, which requires the same quality system infrastructure. It is possible the Flaskworks transition has taken more submission time. It is normal to have a scale up transition included in a pre-approval mfg authorization and it will often include a higher level of automation. The key is that the processing utilizes the same principles as the clinical product process, or there could be more work required. In the case of Flaskworks it does not appear to me there are complicating factors, though routine requirements such as extractables and leachables sometimes uncovers some minor headaches, especially since the technology is new to this type of processing.
I think the expectation is shareholders will know the plan by 12/31 and DCVax will be represented at that March conference, all just my expectations.
Let us know if you see anything differently.

GLTA, Merry Christmas, Happy Holidays and Happy New Year!

[hyperopia]

And just to clarify, I’m not suggesting that a buyout is the reason for Northwest Bio’s absence from the Glioblastoma Drug Development Summit, but merely pointing out that I would think that the first company to release successful results in a Glioblastoma trial (in over 400!) would want to share their successful, unique immunotherapy approach with their peers, perhaps network and seek funding opportunities with potential collaboration partners at a conference that is dedicated to developing treatments for Glioblastoma, and it’s a conference they’ve always attended.

It’s not until March, so there’s still time, but in previous years, Dr. Bosch and Dr. Liau were scheduled to speak months in advance. This seems to be a company that’s still in a quiet period, for whatever reason.
(and yes, it may be that they already have a collaboration partner(s) selected)